{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Diagnostic+Breast+Cancer+Scan", "query": { "intervention": "Diagnostic Breast Cancer Scan" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 156, "total_pages": 16, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Diagnostic+Breast+Cancer+Scan&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-14T03:31:04.039Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07191717", "title": "Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Invasive Breast Carcinoma", "Localized Estrogen Receptor-Positive Breast Carcinoma", "Localized Human Epidermal Growth Factor Receptor (HER2)-Negative Breast Carcinoma" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Imlunestrant", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Radiologic Imaging Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2026-05-18", "completion_date": "2031-04-30", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-09-14T03:31:04.039Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07191717" }, { "nct_id": "NCT00900302", "title": "OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer" ], "interventions": [ { "name": "protein expression analysis", "type": "GENETIC" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "GENETIC", "OTHER", "PROCEDURE" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "120 Years", "sex": "ALL", "summary": "Up to 120 Years" }, "enrollment_count": 98, "start_date": "2005-04", "completion_date": "2011-03", "has_results": false, "last_update_posted_date": "2016-02-10", "last_synced_at": "2026-09-14T03:31:04.039Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00900302" }, { "nct_id": "NCT00572728", "title": "Phase II Study of Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage IIB Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer" ], "interventions": [ { "name": "CT", "type": "PROCEDURE" }, { "name": "18F-FLT", "type": "DRUG" }, { "name": "PET", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2008-12", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2016-12-30", "last_synced_at": "2026-09-14T03:31:04.039Z", "location_count": 27, "location_summary": "Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 16 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Dunedin", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00572728" }, { "nct_id": "NCT05710328", "title": "Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "HER2-Positive Breast Carcinoma", "Invasive Breast Carcinoma" ], "interventions": [ { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Surgical Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 235, "start_date": "2023-05-10", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-09-14T03:31:04.039Z", "location_count": 97, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 81 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05710328" }, { "nct_id": "NCT07016399", "title": "Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Breast Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Epirubicin", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Surgical Procedure", "type": "PROCEDURE" }, { "name": "Ultrasound Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Vandana Abramson", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2025-09-09", "completion_date": "2033-10", "has_results": false, "last_update_posted_date": "2025-10-30", "last_synced_at": "2026-09-14T03:31:04.039Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07016399" }, { "nct_id": "NCT02455453", "title": "Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "18F-FFNP", "type": "DRUG" }, { "name": "CTI/Siemens Biograph 40 PET/CT Scanner", "type": "DEVICE" }, { "name": "Estradiol", "type": "DRUG" }, { "name": "18F-FDG", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 47, "start_date": "2015-04-28", "completion_date": "2019-01-03", "has_results": true, "last_update_posted_date": "2020-01-14", "last_synced_at": "2026-09-14T03:31:04.039Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02455453" }, { "nct_id": "NCT03304587", "title": "Effects of Bright Light on Co-occurring Cancer-related Symptoms in Breast Cancer Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Polysomnography (PSG)", "type": "DIAGNOSTIC_TEST" }, { "name": "Rectal thermistor 400 Series", "type": "DIAGNOSTIC_TEST" }, { "name": "Bright blue-green light", "type": "OTHER" }, { "name": "Dim red light", "type": "OTHER" }, { "name": "Digital foot candle datalogging light meter", "type": "DIAGNOSTIC_TEST" }, { "name": "Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue", "type": "OTHER" }, { "name": "Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance", "type": "OTHER" }, { "name": "Patient-Reported Outcomes Measurement Information System (PROMIS)-Depression", "type": "OTHER" }, { "name": "Patient-Reported Outcomes Measurement Information System (PROMIS)-Physical Function", "type": "OTHER" }, { "name": "Pittsburgh Sleep Quality Index (PSQI)", "type": "OTHER" }, { "name": "Center for Epidemiological Studies - Depression", "type": "OTHER" }, { "name": "Montreal Cognitive Assessment (MoCA)", "type": "OTHER" }, { "name": "European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire (EORTC QLQ-C30)", "type": "OTHER" }, { "name": "Daily Log", "type": "OTHER" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "OTHER" ], "sponsor": "Michigan State University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "FEMALE", "summary": "21 Years and older · Female only" }, "enrollment_count": 30, "start_date": "2017-11-06", "completion_date": "2022-08-31", "has_results": true, "last_update_posted_date": "2025-06-10", "last_synced_at": "2026-09-14T03:31:04.039Z", "location_count": 1, "location_summary": "East Lansing, Michigan", "locations": [ { "city": "East Lansing", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03304587" }, { "nct_id": "NCT01012440", "title": "Role of Positron Emission Mammography (PEM) Flex Solo II Positron Emission Tomography (PET) Scanner in Evaluating Neoadjuvant Chemotherapy Response in Patients With Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "PEM Flex Solo II PET Scanner", "type": "DEVICE" }, { "name": "MRI scan", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "FEMALE", "summary": "18 Years to 75 Years · Female only" }, "enrollment_count": 5, "start_date": "2009-11", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2015-07-27", "last_synced_at": "2026-09-14T03:31:04.039Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01012440" }, { "nct_id": "NCT05554380", "title": "Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Malignant Solid Neoplasm", "Metastatic Malignant Solid Neoplasm", "Unresectable Malignant Solid Neoplasm" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2023-09-22", "completion_date": "2027-02-01", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-09-14T03:31:04.039Z", "location_count": 207, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 167 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Kingman", "state": "Arizona" }, { "city": "Arroyo Grande", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05554380" }, { "nct_id": "NCT02352883", "title": "MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Ductal Breast Carcinoma In Situ" ], "interventions": [ { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" }, { "name": "Therapeutic Surgical Procedure", "type": "PROCEDURE" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Endocrine Therapy", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Cytology Specimen Collection Procedure", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "RADIATION", "DRUG", "OTHER" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 368, "start_date": "2015-03-25", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2025-12-19", "last_synced_at": "2026-09-14T03:31:04.039Z", "location_count": 76, "location_summary": "San Diego, California • San Marcos, California • Greenwich, Connecticut + 56 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Marcos", "state": "California" }, { "city": "Greenwich", "state": "Connecticut" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Meriden", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02352883" } ] }